Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the current treatment paradigm used for polycythemia vera and highlights emerging treatments and their impact on the therapeutic landscape in the future. One of the most promising treatments discussed is ropeginterferon alfa-2b. Dr Kuykendall briefly speaks about the PROUD-PV study (NCT01949805) which has suggested its superiority to hydroxyurea, the current standard treatment available. Dr Kuykendall additionally speaks about another promising agent called rusfertide, a hepcidin-mimetic which has been shown to reduce the need for phlebotomy. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
17 авг 2021
